Bis(hydroxyphenylethyl)deoxyguanosine adducts identified by phosphorus-32-postlabeling and four-sector tandem mass spectrometry: unanticipated adducts formed upon treatment of DNA with styrene 7,8-oxide.
The phosphorus-32 (P-32) postlabeling procedure was in order to detect covalent xenobiotic adducts in the enzymic hydrolysate of native calf thymus DNA modified during incubation with styrene-oxide (96093). Six covalent adducts were detected by this method, three of which were very hydrophobic, indicating they may have been unusually modified. These three were studied and their structural nature presented as isomeric bis substituted guanine mononucleotides. These three represented less than 2% of the total adducts detected. Elemental composition was determined by measuring their accurate masses by high resolution mass spectrometry. This demonstrated the incorporation of 2 moles of hydroxyphenylethyl moieties. Interpretation of high energy collision induced dissociation mass spectra, along with ultraviolet/visible and fluorescence spectrophotometry allowed the identification of N2-(2- hydroxy-1-phenylethyl)-O6-(2-hydroxy-2-phenylethyl)-2'- deoxyguanosine 3'-phosphate, N2-(2-hydroxy-1-phenylethyl)-O6-(2- hydroxy-1-phenylethyl)-2'-deoxyguanosine 3'-phosphate, and N1,N2- bis(2-hydroxy-1-phenylethyl)-2'-deoxyguanosine-3'-phosphate. The other most abundant adducts represented about 65% of the total covalent binding and were identified as depurinated N7-substituted guanines using tandem mass spectrometry with ultraviolet/visible spectroscopy. The authors recommend the use of combined advanced techniques for a comprehensive strategy which insures complete structural identification of all xenobiotic/DNA adducts.
Links with this icon indicate that you are leaving the CDC website.
The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
You will be subject to the destination website's privacy policy when you follow the link.
CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website.
For more information on CDC's web notification policies, see Website Disclaimers.
CDC.gov Privacy Settings
We take your privacy seriously. You can review and change the way we collect information below.
These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.
Cookies used to make website functionality more relevant to you. These cookies perform functions like remembering presentation options or choices and, in some cases, delivery of web content that based on self-identified area of interests.
Cookies used to track the effectiveness of CDC public health campaigns through clickthrough data.
Cookies used to enable you to share pages and content that you find interesting on CDC.gov through third party social networking and other websites. These cookies may also be used for advertising purposes by these third parties.
Thank you for taking the time to confirm your preferences. If you need to go back and make any changes, you can always do so by going to our Privacy Policy page.